Research work · 2021

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Yuriy Janjigian, Kohei Shitara, Markus Hermann Moehler

The Lancet

Read free full text

DOI: 10.1016/s0140-6736(21)00797-2